GSK's Promacta shows long-term efficacy in Phase III
This article was originally published in Scrip
GlaxoSmithKline's oral thrombopoietin receptor agonist, Promacta (eltrombopag), has shown long-term efficacy in chronic immune (idiopathic) thrombocytopenic purpura (ITP), in the six-month Phase III RAISE study whose results were recently presented at American Society of Hematology (ASH) meeting in San Francisco.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.